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Abstract: Aim: To investigate whether the presence of left ventricular myocardial dysfunction
(LVMD) assessed by Tei index (LVTX) impacts the outcomes of healthy infants with Respiratory
Syncytial Virus Bronchiolitis (RSVB). To explore whether N-terminal pro-B-type natriuretic peptide
(NT-proBNP) increases the accuracy of traditional clinical markers in predicting the outcomes.
Methods: A single-centre, prospective, cohort study including healthy infants aged 1–12 months
old admitted for RSVB between 1 October 2016 and 1 April 2017. All patients underwent clinical,
laboratory and echocardiographic evaluation within 24 h of admission. Paediatric intensive care unit
(PICU) admission was defined as severe disease. Results: We enrolled 50 cases of RSVB (median age
of 2 (1–6.5) months; 40% female) and 50 age-matched controls. We observed higher values of LVTX in
infants with RSVB than in controls (0.42 vs. 0.36; p = 0.008). Up to nine (18%) children presented
with LVMD (LVTX > 0.5), with a higher incidence of PICU admission (89% vs. 5%; p < 0.001). The
diagnostic performance of NT-proBNP in predicting LVMD was high (area under the receiver operator
characteristic curve (AUC) 0.95, CI 95% 0.90–1). The diagnostic yield of the predictive model for PICU
admission that included NT-proBNP was excellent (AUC 0.945, CI 95% 0.880–1), and significantly
higher than the model without NT-proBNP (p = 0.026). Conclusions: LVMD could be present in
healthy infants with RSVB who develop severe disease. NT-proBNP seems to improve traditional
clinical markers for outcomes.
Keywords: respiratory syncytial virus; NT-proBNP; echocardiography; pulmonary hypertension;
myocardial dysfunction; tissue doppler imaging; Tei index; biomarkers; infants
1. Introduction
Respiratory Syncytial Virus Bronchiolitis (RSVB) is the leading cause of lower respiratory infection
and hospital admission among children up to 2 years of age worldwide [1]. Approximately 2–6% cases
of RSVB will develop a severe form of the disease, requiring admission to the paediatric intensive care
unit (PICU) and mechanical ventilation (MV) [1,2]. RSVB constitutes approximately 13% of all PICU
admissions [2]. Current guidelines recognize the identification of specific risk factors (congenital heart
disease (CHD), chronic lung disease (CLD), prematurity, etc.) and clinical evaluation as the best tools
to assess severity, predict evolution and tailor management [3].
Cardiovascular involvement seems to be a relevant prognostic factor in RSVB. Cardiovascular
complications are present in up to 9% of cases of RSVB and constitute the second most common
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extrapulmonary manifestation after infectious complications [4]. These events usually present in an
abrupt and unexpected manner in children with severe RSVB, and infants with CHD are particularly
susceptible to these complications and adverse outcomes [5]. Interestingly, nearly half of the children
admitted to PICU with RSVB are healthy prior to the clinical event [2]. In these patients, the presence
of acute lung injury secondary to RSVB can also lead to important cardiovascular effects, especially
elevated pulmonary vascular resistance and overload on the right ventricle (RV) [6–8]. Moreover,
previous studies assessing the plasma levels of cardiac troponin in RSVB suggest an underrecognized
yet clinically significant incidence of myocardial damage in this population [9–11]. Furthermore, RV
global dysfunction in ventilated healthy infants has been reported [12]. Recently, we found that mild
to moderate forms of pulmonary hypertension (PH) could impact the outcome of healthy infants with
RSVB [13].
Adverse RV–LV interactions and left ventricle (LV) myocardial dysfunction (LVMD) are emerging
as important determinants of PH outcomes. PH can induce complex changes in LV geometry
and causes an abnormal relaxation and non-uniform contraction pattern in the LV wall, leading to
LVMD [14–16]. However, most studies in healthy infants with RSVB found no abnormalities when
assessing LVMD through conventional echocardiographic parameters [12,13,17–19]. Remarkably, there
are no studies to date assessing LVMD in RSVB by more sensitive methods such as tissue Doppler
imaging (TDI) echocardiography.
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a hormone synthesized and released
into the circulation by ventricular myocytes in response to pressure/volume overload and an increase
in myocardial wall stress [20]. Elevated serum NT-proBNP levels have been defined as a powerful
biomarker in the diagnosis of PH, and both LVMD and RV myocardial dysfunction (RVMD) secondary
to pulmonary diseases [21–25]. Of note, we recently showed how NT-proBNP could be considered an
adequate biomarker for PH in previously healthy infants with RSVB [13].
In this study, we aimed to investigate the presence of adverse RV–LV interactions and LVMD
(assessed by TDI-echocardiography) in previously healthy infants with RSVB. We hypothesized that
acute PH with RV pressure overload may indeed have a direct impact on LV performance. We also
hypothesized that those infants with LVMD are prone to developing a more severe form of disease.
Finally, we sought to test NT-proBNP as a biomarker for LVMD and explore whether NT-proBNP
increases the accuracy of traditional clinical markers in predicting the severity of the disease.
2. Materials and Methods
2.1. Design, Settings and Study Population
This was a single-centre, prospective, cohort study including infants aged 1–12 months old admitted
to the paediatric department in our institution (a tertiary university-affiliated hospital in Spain) due to
RSVB (determined by a confirmed Respiratory Syncytial Virus (RSV) antigen test) between 1 October
2016 and 1 April 2017. All patients underwent clinical, laboratory and echocardiographic evaluation
within 24 h of admission. We excluded patients with co-existing CHD or CLD, prematurity, those that
received MV or intravenous fluid before assessment, and those with poor-quality echocardiographic
images or incomplete medical records. Severe cases were screened for coinfection and, if present, were
also excluded. The control group consisted of age-matched healthy infants who underwent evaluation
for heart murmur at our paediatric cardiology outpatient clinic during the study period. These controls
followed the same echocardiographic protocol as study patients. Our Institutional Review Board
approved the study. Informed consent was obtained for all patients.
2.2. Clinical and Laboratory Assessment and Outcomes
The bronchiolitis score of Sant Joan de Déu (BROSJOD) [26] was used to assess severity at
admission clinically. A BROSJOD score greater than 10 points is indicative of a severe clinical state.
Venous pH and pCO2 were determined and respiratory acidosis (RA) was diagnosed when pH
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< 7.35 and pCO2 > 45 mmHg. Plasma NT-proBNP levels at admission were determined using a
commercially available electrochemiluminescent immunoassay kit (ElecSys 2010, Roche Diagnostics).
The primary outcome was PICU admission during hospitalization. PICU admission criteria for RSVB
at our institution include the presence of: apnea, extreme bradycardia, the need for respiratory support
greater than high-flow nasal cannula oxygen therapy or inotropic support.
2.3. Echocardiographic Assessment
Standard techniques to obtain M-mode, two-dimensional and Doppler (color, pulsed, continuous
and TDI) echocardiograms were performed by the same experienced paediatric cardiologist (RGM) as
recommended in the guidelines for the paediatric echocardiogram [27]. Images were obtained using a
Phillips IE33 ultrasound scanner with an 8 or 12-MHz sectorial transducer. Each examination was
recorded, and all the studies were reviewed off-line by 2 observers (RGM and PRA), who were blinded
to the patient’s clinical profile. All echocardiographic measurements represent the average of 3 beats.
Control and case echocardiographic data were deidentified before data analysis. Figures 1 and 2 show
the main echocardiographic measures used in this study.
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annular velocity). Em (TDI-derived early diastolic mitral annulus velocity). Am (TDI-derived late 
diastolic mitral annulus velocity). PW-E (PW-derived mitral peak early diastolic velocity). PW-A 
(PW-derived mitral peak late diastolic velocity). IVCT (TDI-derived isovolumic contraction time). 
IVRT (TDI-derived isovolumic relaxation time). ET (TDI-derived ejection time). 
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2.3.1. Right-Sided Echocardiographic Assessment
T e RV end-diastolic di meter (RVEDD) and the RV/LV ratio (RVLVr) were used as indicators
of RV dilation. RV systolic function was assessed by the tricuspid annular plane systolic excursion
(TAPSE) [28], and by the tissue Doppler imaging (TDI) derived peak systolic annular velocity at the
tricuspid level of the RV free wall (St). RV Tei index (RVTX) was used as a measurement of global
(systolic and diastolic) RV function. It was calculated using the TDI-derived isovolumic contraction
(IVC), isovolumic relaxation (IVR) and ejection time (ET) intervals (measured at the lateral part of the
tricuspid annulus) as previously described [29]. RV systolic pressure was calculated by the systolic
gradient of the tricuspid regurgitation jet (TRJG) and using the simplified Bernoulli equation [30].
Due to the absence of an adequate tricuspid regurgitation jet in most patients, the RV outflow tract
acceleration time/ejection time ratio (ATET) [31], the LV systolic eccentricity index (LVEI) [32], and
the presence of septal flattening at the end of systole on the qualitative assessment were also used
as indicators of RV systolic pressures [30]. The LVEI was also used as a measurement of leftward
displacement of the interventricular septum (IVS).
2.3.2. Left-Sided Echocardiographic Assessment
The LV end-diastol c di meter (LVEDD) was used as an indicator of LV dilation. The LV shortening
fraction (LVSF) and the tissue Doppler imaging (TDI)-derived peak systolic annular velocity at the
mitral level of the LV free wall (Sm) were used to assess LV systolic function. To assess the diastolic LV
function, we obtained the mitral peak early (E) and late (A) diastolic velocity using the pulsed wave
Doppler of the mitral valve inflow. Also, the TDI-derived early diastolic mitral annulus velocity (Em)
was measured at the lateral part of the mitral annulus. The E/Em ratio and E/A ratio were calculated as
indicators of LV filling pressures. LV Tei index (LVTX) was used as a measurement of global (systolic
and diastolic) LV function. It was calculated using the TDI-derived isovolumic contraction (IVC),
isovolumic relaxation (IVR) and ejection time (ET) intervals (measured at the lateral part of the mitral
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annulus) as previously described [29]. Cui and Robertson reported in 2006 that the mean normal value
of the LVTX for infants aged 1–12 months is 0.35 (0.09), and that a LVTX less than 0.5 is the upper limit
of normal (2Zscore) [33]. Therefore, a LVTX > 0.5 was defined as LVMD in this study.
2.4. Reproductibility
To explore intra-observer and inter-observer agreement, 30 echocardiographic studies were
randomly selected and analysed offline. To estimate the intra-observer agreement, the first observer
(RGM) remeasured the LVTX, RVTX and LVEI with a 30-day interval blinded to previous measurements
and patient information. To assess the inter-observer agreement, the means of both observers for each
measurement were compared.
2.5. Statistical Analysis
Continuous data are presented as the median (range) or mean (standard deviation) after testing
for normality with the Shapiro–Wilk test; categorical data are presented as frequencies and percentage.
Mean comparison was performed using the Student’s t test or Wilcoxon Mann–Whitney test as
appropriate. Proportions were compared using the Chi-square test or exact methods as necessary.
Pearson and Spearman coefficients were used to assess correlations between continuous data. A
receiver operator curve (ROC) analysis was used to determine the diagnostic accuracy of NT-proBNP
for LVMD. The best cut-off value of NT-proBNP to detect LVMD was empirically estimated based on the
Liu method, and values of sensitivity (Se), specificity (Sp), negative predictive value (NPV) and positive
predictive value (PPV) were calculated for the obtained cut point. We selected 2 predefined predictive
models for PICU admission. The selection of the included variables was based on the theoretical
background and the exploratory analysis. Model 1 (proposed model) included age, BROSJOD score
and NT-proBNP levels and model 2 (traditional model) included age and BROSJOD score. Prediction
models were evaluated through multivariate logistic regression analysis. The discriminating ability
of each model was assessed by the area under the receiver operator characteristic (AUC) curve. The
AUCs from the obtained models were then compared by using the DeLong method [34] to determine
whether any model resulted in increased predictive accuracy. The reliability of echocardiographic
measurements was evaluated with the intra-class correlation (ICC) coefficients and Bland–Altman (BA)
analysis [35]. Based on the 95% confident interval of the ICC coefficients, values less than 0.5, between
0.5 and 0.75, between 0.75 and 0.9, and greater than 0.90 were considered indicative of poor, moderate,
good, and excellent reliability, respectively. All the statistical analyses were performed using the Stata
13.0. (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.). A
p value < 0.05 was considered statistically significant.
3. Results
3.1. Baseline Characteristics and Outcomes of Patients with RSVB
We enrolled a total of 50 cases of RSVB with a median age of 2 (1–6.5) months (40% female). The
control group consisted of 50 healthy infants with no differences regarding age, sex or body surface area
(BSA) distribution (Table 1). RSVB patients were admitted 2.76 (1.23) days after the initial symptoms,
with a median BROSJOD score of 6 (1–14), a median SpO2 of 93% (87–98%), and a median heart rate of
118 bpm (89–179 bpm). Up to nine (18%) cases presented RA and a BROSJOD score > 10. A total of
10 (20%) cases needed PICU admission within 1.20 (0.38) days from hospitalization (length of PICU
stay 5 (2–9) days) and were classified as having severe RSVB. A total of 3 of these 10 cases required
MV and seven of them required continuous positive airway pressure (CPAP). No cases of arrhythmia
different from sinus tachycardia were observed. No patient required inotropic support and none of the
included patients died.
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Table 1. Baseline clinical and laboratory characteristics of the Respiratory Syncytial Virus Bronchiolitis
(RSVB) population and comparison with controls.
Variable RSVB Group (n = 50) Control Group (n = 50) p Value
Age (months) 2 (1–6.5) 2 (1–9) 0.591
Female sex 20 (40) 23 (46) 0.545
BSA (m2) 0.28 (0.18–0.43) 0.27 (0.18–0.42) 0.617
Time of symptoms (days) 2.76 (1.23) - -
BROSJOD score 6 (1–14) - -
SpO2 (%) 93 (87–98) 99 (95–100) <0.001
Heart rate (bpm) 118 (89–179) 109 (87–133) 0.002
pH 7.36 (7.22–7.45) - -
pCO2 42 (31–71) - -
Nt-proBNP (pg/mL) 511 (62–5532) - -
Respiratory Acidosis 9 (18) - -
BROSJOD > 10 9 (18) - -
PICU admission 10 (20) - -
BSA (body surface area); PICU (paediatric intensive care unit); BROSJOD score (bronchiolitis score of Sant Joan de
Déu); Nt-proBNP (N-terminal pro-B-type natriuretic peptide); PICU (Paediatric intensive care unit).
3.2. Echocardiographic Alterations in Patients with RSVB
The RSVB group had a higher proportion of pericardial effusion (34% vs. 6%; p < 0.001). All cases
of pericardial effusion were mild and did not require any treatment. We observed higher values of
LVTX (0.42 vs. 0.36; p = 0.008) in infants with RSVB than in controls (Figure 3). The RSVB group also
presented more cases of septal flattening (28% vs. 6%; p = 0.003), and higher TRJG (27 vs. 22 mmHg;
p = 0.013), RVTX (0.39 vs. 0.36; p = 0.005) and LVEI (1.08 vs. 1; p < 0.001) than the control group. There
were no differences between RSVB and control groups regarding echocardiographic parameters of
ventricular dimensions, systolic or diastolic function (Table 2).
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Table 2. Baseline echocardiographic characteristics of the RSVB population and comparison
with controls.
Variable RSVB Group (n = 50) Control Group (n = 50) p Value
Pericardial effusion 17 (34) 3 (6) <0.001
Left ventricle
LVDD (mm) 21 (17–29) 21 (14–28) 0.470
LVSF (%) 38.5 (5.6) 39 (5) 0.851
Sm (cm/s) 8.7 (1.6) 9 (1.2) 0.573
Mitral E (cm/s) 98 (79–125) 96 (76–123) 0.798
Mitral A (cm/s) 75 (49–97) 71 (51–93) 0.259
Mitral E/A 1.25 (0.93–1.98) 1.43 (1–2) 0.200
Mitral Em (cm/s) 9.4 (6–5–14) 10 (6.6–15) 0.110
Mitral Am (cm/s) 9 (5–15) 9 (6–13) 0.182
Mitral E/Em (cm/s) 10.2 (5.8–20) 9.8 (5.2–17) 0.283
LVTX 0.42 (0.25–0.65) 0.36 (0.26–0.47) 0.008
Right ventricle
RVDD (mm) 10 (7–19) 10 (7–14) 0.264
RV/LV ratio 0.49 (0.28–0.80) 0.46 (0.28–0.76) 0.473
TAPSE (mm) 12.3 (1.6) 12 (1.8) 0.624
St (cm/s) 8.5 (2) 9.1 (1.7) 0.901
RVTX 0.39 (0.25–0.65) 0.37 (0.26–0.48) 0.005
Adequate TRJ 25 (50) 30 (60) 0.633
TRJG (mmHg) 27 (18–47) 22 (16–34) 0.013
ATET 0.38 (0.06) 0.39 (0.03) 0.288
LVEI 1.08 (0.98–1.45) 1 (0.95–1.12) <0.001
Septal Flattening 14 (28) 3 (6) 0.003
LVDD (left ventricle diastolic diameter); LVSF (left ventricular shortening fraction); LVTX (left ventricular Tei index);
RVDD (right ventricular diastolic diameter); RV (right ventricle); LV (Left ventricle); TAPSE (tricuspid annular
plane systolic excursion); RVTX (Right ventricular Tei index), TRJ (tricuspid regurgitation jet); TRJG (tricuspid
regurgitation jet gradient); ATET (right ventricular acceleration time/right ventricular ejection time ratio); LVEI
(systolic left ventricular eccentricity index).
3.3. Adverse LV–RV Interactions in Patients with RSVB
In the RSVB group, increased LVTX was related to echocardiographic parameters indicating
higher RV dimensions (Rho RVDD = 0.56, Rho RVLVr = 0.60), higher RV pressures (Rho TRJG = 0.54,
Rho ATET = −0.50, Rho LVEI = 0.77), and decreased RV global function (Rho RVTX= 0.74). We did not
find associations of echocardiographic measurements of RV systolic function (TAPSE and St) with
LVTX (Table 3 and Figure 4).
Table 3. Correlation coefficients between LVTX and RV echocardiographic parameters and plasmatic
NT-proBNP levels in RSVB cases.
Variable Rho p Value
RVDD 0.56 0.003








RVDD (right ventricular diastolic diameter); RV (right ventricle); LV (Left ventricle); TAPSE (tricuspid annular
plane systolic excursion); RVTX (Right ventricular Tei index); TRJ (tricuspid regurgitation jet); TRJG (tricuspid
regurgitation jet gradient); ATET (right ventricular acceleration time/right ventricular ejection time ratio); LVEI
(systolic left ventricular eccentricity index).
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Time of symptoms (days) 2 (1.5) 3 (1–7) 0.488 
BROSJOD score 11 (9–14) 6 (1–13) < 0.001 
SpO2 (%) 90 (87–93) 94 (88–98) < 0.001 
Heart rate (bpm) 135 (100–164) 116 (89–179) 0.141 
pH 7.3 (7.25–7.42) 7.36 (7.22–7.45) 0.115 
pCO2 (mmHg) 54 (31–61) 41 (31–71) 0.009 
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Figure 4. A representation of the correl ti f et een LVTX and param ters of RV function
(RVTX, right panel) and RV pressures (LVEI, left panel). LVTX (Left ventricular Tei index). RVTX (right
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3.4. LVMD in Patients with RSVB
We found LVMD, defined by a LVTX > 0.5, in nine (18 ) patients with RSVB (Table 4). LVMD
was ssociated with PICU admission (89% vs. ; .001). These patients pr sented with a higher
BROSJOD score (11 vs. 6; p < 0.001), l vs. 94%; p < .001), more ca es of RA (55% vs.
9%; p = 0. 01), and higher T-pr ls (2221 pg/mL vs. 377 pg ml; p < .001) than those with
a nor l cardial function. The LVTX wa als strongly correlated with NT-proBNP levels
(Rho = 0.73) (Figure 5).
Table 4. Clinical and laboratory characteristics in patients with RSVB and LVMD, and comparison with
those patients with normal LV function.
Variable LVMD (n = 9; 18%) Normal LV Function (n = 41; 82%) p Value
Age (months) 2 (1–4.5) 2 (1–6.5) 0.538
Female sex 2 (22) 18 (44) 0.230
BSA (m2) 0.29 (0.18–0.33) 0.28 (0.18–0.43) 0.742
Time of symptoms (days) 2 (1.5) 3 (1–7) 0.488
BROSJOD score 11 (9–14) 6 (1–13) <0.001
SpO2 (%) 90 (87–93) 94 (88–98) <0.001
Heart rate (bpm) 135 (100–164) 116 (89–179) 0.141
pH 7.3 (7.25–7.42) 7.36 (7.22–7.45) 0.115
pCO2 (mmHg) 54 (31–61) 41 (31–71) 0.009
Nt-proBNP (pg/mL) 2221 (891–5532) 377 (62–1779) <0.001
PICU admission 8 (89) 2 (5) <0.001
LVMD (left ventricular myocardial dysfunction); BSA (Body surface area); PICU (paediatric intensive care unit).
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3.5. NT-ProBNP as Biomarker for LVMD
The diagnostic performance of NT-proBNP to predict LVMD in infants with RSVB resulted in an
area under the ROC curve of 0.91 (CI95% 0.79–0.98) (Figure 6). The best estimated cut-off value to
predict LVMD on echocardiography was 1500 pg/mL, correctly classifying 92% of cases, with a Se of
0.80 (CI95% 0.49–0.94), Sp of 0.95 (CI95% 0.83–0.98), a PPV of 0.80 (CI95% 0.49–0.94), and an NPV of
0.95 (CI95 0.87–0.99) (Youden index 0.75).
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3.6. Clinical and Laboratory Predictors of PICU Admission in RSVB
e developed two different and predefined prediction models for PICU admission in RSVB. The
variables used were clinical parameters that are traditionally used to assess severity in RSVB (age and
clinical score), and NT-proBNP as biomarker for LVMD. Model 1 (the proposed model) included age < 3
months, BROSJOD score > 10, and NT-proBNP > 1500 pg/mL. Model 2 (the traditional model) included
age < 3 months and BROSJOD score > 10. The diagnostic yield of model 1 for PICU admission was
excellent (AUC 0.945, CI95% 0.880–1), and significantly higher than the yield for model 2 (p = 0.026). In
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model 1, the presence of NT-proBNP levels > 1500 pg/mL was the only independent predictive factor
for PICU admission in RSVB, with an OR 27.03 (CI95% (1.50–487), p = 0.025) (Table 5 and Figure 7).
Table 5. Univariate and Multivariate logistic regression analysis performed to find a predictive model
for PICU admission during hospitalization in our RSVB cohort.
Variable Univariate AnalysisOR (CI 95%) p Value
Multivariate Analysis
OR (CI 95%) p Value pseudoR2
Model 1 <0.001 0.51
Age < 3 months 0.88 (0.19–4.04) 0.875 0.71 (0.66–7.58) 0.777
BROSJOD score > 10 44.33 (6.22–315.50) <0.001 3.06 (0.12–76.44) 0.494
NT-proBNP > 1500 pg/mL 76 (9.27–622) <0.001 27.03 (1.50–487) 0.025
Model 2 <0.001 0.38
Age < 3 months 0.88 (0.19–4.04) 0.875 0.52 (0.06–4.21) 0.541
BROSJOD score > 10 44.33 (6.22–315.50) <0.001 49.27 (6.38–380) <0.001
OR (Odds ratio); CI (Confidence interval).
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3.7. Reproductibility
The intra-observer and inter-observer agreement for LVTX, RVTX and LVEI were good or excellent,
with all ICC coefficients > 0.75 (Table 6).
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Table 6. Intra-observer and inter-observer agreement scores for the main echocardiographic
measurements performed in this study, the left ventricular and right ventricular Tei indexes (LVTX and
RVTX), and the systolic left ventricular eccentricity index (LVEI).
Variable
Intra-observer (RG.M) Inter-observer (RG.M and PR.A)
ICC (95% CI) BA (LOA) ICC (95% CI) BA (LOA)
LVTX 0.95 (0.93–0.99) 0.00 (−0.03–0.03) 0.84 (0.74–0.93) −0.01 (−0.07–0.05)
RVTX 0.97 (0.95–0.99) −0.002 (−0.02–0.02) 0.86 (0.77–0.95) −0.015 (−0.07–0.04)
LVEI 0.89 (0.82–0.96) −0.007 (−0.04–0.03) 0.84 (0.73–0.94) −0.01 (−0.05–0.03)
ICC (interclass coefficient); CI (confidence interval); BA (Bland–Altman average); LOA (limits of agreement).
4. Discussion
The main finding of our study is that LVMD was observed at the early stages of the disease in up
to 18% of previously healthy infants with RSVB when assessed by DTI-derived LVTX. The LVMD was
associated with a more severe respiratory state, PICU admission, and echocardiographic signs of RV
pressure overload and RVMD, indicating the presence of adverse RV–LV interactions in cases of severe
RSVB. Also, we observed that NT-proBNP accurately identified LVMD. Moreover, we found an added
benefit to the addition of NT-proBNP to the clinical evaluation in predicting the development of severe
disease in this population.
CHD is an important cause of morbidity and mortality in RSVB [5]. This may be related to multiple
physiological factors including baseline compromised cardiorespiratory function and the potential
development of PH. However, little is known about LVMD and its association with RV function,
pulmonary hemodynamics, and outcomes in previously healthy infants with RSVB. In accordance
with the literature, the present study reveals that conventional parameters of myocardial function are
not altered in RSVB [17–19]. Only one previous study has assessed myocardial performance using the
TEI index in RSVB [12]. Our results are consistent with those reported by Thorburn et al. who found
RVMD in ventilated patients with severe RSVB. However, they did not demonstrate any association
between PH and RVMD. This may be due to the use of TRJG alone as an echocardiographic marker of
RV pressure, and the presence of PH may had been underestimated. In a recent work from our group,
we used a combination of different echocardiographic parameters to assess RV pressures and PH was
reported in up to 22% of RSVB cases at early stages of the disease. In agreement with Thorburn et al.,
we did not find an association between PH and RV or LVMD [13]. We assessed ventricular function
only by conventional parameters (TAPSE and LVSF).
To the best of our knowledge, this is the first study to evaluate LVMD using TDI-derived LVTX,
and to assess RV–LV interactions in infants with RSVB. LVTX, which includes both systolic and
diastolic time intervals to assess the global cardiac dysfunction, is an easily performable, recordable
and reproducible parameter with normal reference values that can be applied to the entire spectrum
of the paediatric population, regardless of age, heart rate, and BSA [36]. Using LVTX, we found
LVMD in nearly 20% of cases. The RV shares muscle fibres, the inter-ventricular septum (IVS), and the
pericardial sac with the LV. Consequently, changes in RV affect the LV, a concept termed ventricular
interdependence [16,37,38]. In this study, we observed a moderate to strong correlation between LVTX
and leftward displacement of the IVS (LVEI), raised RV pressures (TRGJ, ATET) and reduced RV global
function (RVTX), confirming the presence of adverse RV–LV interactions in cases with severe RSVB.
These results do not imply casualty, but in the absence of primary (myocarditis, cardiomyopathies,
CHD) or secondary (sepsis, severe acidosis...) causes of LVMD, we suggest RV pressure overload and
RV dysfunction due to pulmonary disease as the underlying condition for LVMD in our RSVB cohort.
Recent paediatric studies have reported that PH can induce complex changes in LV geometry and causes
an abnormal relaxation and non-uniform contraction pattern in the LV wall, leading to LVMD [14–16],
supporting our hypothesis. These observations could add new insights into the pathophysiology of
RSVB, highlighting a key role of the cardiovascular system, especially LV myocardial performance in
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this setting. Validating our findings in similar populations in different settings may also provide a basis
to implement new therapeutic approaches for this disease, which currently has no effective treatment.
Possible new therapeutic approaches may include the initiation of early respiratory support in cases
with increased NT-proBNP, pulmonary vasodilators to reduce RV pressure overload and avoiding
epinephrine in cases with LVMD.
In RSVB, the major goals are the prevention and early identification of infants at risk for severe
disease in order to provide the best management options and decrease morbidity. Current guidelines
recommend only clinical observation for this purpose in infants without known comorbidities [3].
However, most clinical scores for RSVB are not well validated and fail to predict outcomes [39,40].
Recently, the BROSJOD score, a validated clinical score for RSVB, has shown a strong capacity to predict
the evolution in the course of RSVB, but it is not yet generalizable due to the single-centre character of
the study [26]. In this context, the identification of novel biomarkers with adequate predictive value
for disease severity in RSVB is an area of increasing research interest. Neutrophins, cytokines and
leukotrienes are promising but not widely available for clinical practice [41]. Previous studies have
also tested cardiac troponin as a prognostic marker with inconsistent results [9,10,12,13]. The LVMD
found in our population was only identifiable by TDI-echocardiography, suggesting that it was mild
in most of our patients. Nevertheless, this does not mean that LVMD is inconsequential in RSVB.
Remarkably, most patients with LVMD presented with severe disease at admission and most of them
required PICU admission. Of note, we included non-ventilated infants at early stages of the disease
(mean time of 2.76 (1.23) days after the initial symptoms), when the patients had not yet been admitted
to the PICU, increasing the prognostic value of our results. Therefore, assessing and understanding
myocardial function in RSVB seems to be relevant.
Another interesting finding of our study was that NT-proBNP could be a useful biomarker for
LVMD and subsequent outcomes in RSVB. Previous studies have also documented the correlation
between LVTX and NT-proBNP plasma levels [42–44]. We explored the diagnostic accuracy of
NT-proBNP to detect LVTX > 0.50, which was high (AUC 0.91), with an optimal cut-off value of 1500
pg/mL (Se 0.80, Sp 0.95, PPV 0.80, NPV 0.95). We also tested the benefit in adding NT-proBNP to the
currently used clinical data to assess outcomes in RSVB. Although the predictive models including age
and BROSJOD score presented a high predictive accuracy for PICU admission in our population, we
observed that the addition of NT-proBNP to this model increased the predictive value significantly, and
that NT-proBNP was the only independent factor within the analysed values that predicted a severe
course of the disease. Most cases of RSVB are mild forms manageable on an outpatient basis without
the need for laboratory exams. Nevertheless, many children sufficiently ill to require hospitalization
will routinely have laboratory studies drawn. Adding NT-proBNP measurement to these studies could
be useful in order to identify high-risk patients who benefit from echocardiographic screening to PH,
RVMD or LVMD. Based on our results, it might be reasonable to perform an echocardiogram in those
patients with NT-proBNP levels > 1500 pg/mL.
This work included some limitations. Our study was performed at a single centre and with a
relatively small size. We excluded irritable or unstable patients, where the technical difficulties due to
respiratory comorbidity and the patient’s inability to tolerate the evaluation could impact the results.
The PICU admission criteria and, subsequently, the definition of severe diseases in the study are based
on the protocol of our hospital, which can vary between institutions. Therefore, a larger multicentre
cohort study including irritable or unstable cases and with uniform PICU admission criteria may be
needed for the verification and generalization of our results. Finally, the assessment of myocardial
function and PH on echocardiography was not confirmed by an independent gold-standard method,
such as cardiac magnetic resonance imaging or right heart catheterization, and therefore some patients
could have been misclassified.
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5. Conclusions
Adverse RV–LV interactions and LVMD could be present in healthy infants with RSVB during the
early stages of the disease, negatively impacting the outcome. NT-proBNP seems to be an adequate
biomarker for LVMD. Adding NT-proBNP to traditional clinical markers to assess outcomes in RSVB
could improve the early detection of those cases that will develop a severe illness. Future research is
need in order to confirm these results and to design new therapeutic approaches based on them.
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